QuidelOrtho Q3 revenue $744M, GAAP loss $0.19/sh, adj EPS $0.90; maintains FY guidance

QuidelOrtho Corp

2023-Q3 EPS reported -$0.26 revenue$2,255,200,000

Total revenue $744.0M, down from $783.8M YoY; respiratory revenue declined 21% as anticipated.
GAAP net loss $(13)M, diluted loss per share $(0.19); adjusted diluted EPS $0.90 vs $1.85 prior year.
Non-respiratory revenue grew 2% (constant currency) driven by Labs business strength.
Adjusted EBITDA $169M with 23% margin; company paid down $52M on term loan in Q3, $175M year-to-date.
Fiscal 2023 guidance maintained: total revenue $2.88–$3.08B, adjusted EPS $4.85–$5.30.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

QuidelOrtho Corp reported fiscal year 2023 results: revenue Total revenues (reported) $2.88 - $3.08 billion, EPS Adjusted diluted EPS $4.85 - $5.30. Guidance reaffirmed.

Period: fiscal year 2023
Revenue: Total revenues (reported) $2.88 - $3.08 billion
EPS: Adjusted diluted EPS $4.85 - $5.30
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

The Company is maintaining its 2023 financial guidance, provided on August 8, 2023, as follows: Total revenues (reported) $2.88 - $3.08 billion

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

QuidelOrtho Corp reported third quarter ended October 1, 2023 results: revenue Third quarter revenue was $744 million, EPS Third quarter GAAP diluted loss per share was $(0.19); adjusted diluted earnings per share (“EPS”) was $0.90.

Period: third quarter ended October 1, 2023
Revenue: Third quarter revenue was $744 million
EPS: Third quarter GAAP diluted loss per share was $(0.19); adjusted diluted earnings per share (“EPS”) was $0.90
Result: reported results

Exact text from the filing

On November 1, 2023, QuidelOrtho Corporation (“QuidelOrtho”) issued a press release announcing the financial results for its third quarter ended October 1, 2023 and will hold an earnings conference call at 2:00 p.m., Pacific Time, on November 1, 2023 to discuss such results.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Period: third quarter ended October 1, 2023
Revenue: Third quarter revenue was $744 million
EPS: Third quarter GAAP diluted loss per share was $(0.19); adjusted diluted earnings per share (“EPS”) was $0.90
Result: reported results

Exact text from the filing

Third quarter revenue was $744 million, as reported, driven by strong respiratory demand and continued strength in non-respiratory businesses

View on SEC.gov

Browse all earnings releases →

QuidelOrtho Corp filing history →

Source: SEC EDGAR

accession 0001906324-23-000056

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.